Welcome to our dedicated page for Invivyd SEC filings (Ticker: IVVD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Invivyd, Inc. (Nasdaq: IVVD) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Invivyd is a Delaware-incorporated biopharmaceutical company whose common stock is listed on The Nasdaq Stock Market LLC under the symbol IVVD, as noted in multiple Form 8-K reports.
Through this page, readers can review Invivyd’s current and historical Form 8-K filings, which describe material events such as public offerings of common stock and pre-funded warrants, entry into underwriting agreements, clinical and regulatory milestones for its monoclonal antibody programs, and corporate governance changes. Examples include 8-Ks detailing underwritten offerings to fund commercial preparedness for VYD2311, research and development for RSV and measles programs, and formation of the SPEAR Study Group to study monoclonal antibody therapy for Long COVID and COVID-19 post-vaccination syndrome.
Invivyd’s filings also reference press releases on topics such as U.S. IND clearance and FDA alignment on the pivotal clinical program for VYD2311, Fast Track designation for VYD2311, selection of the RSV antibody candidate VBY329, and financial results for recent quarters. Other 8-Ks note Nasdaq correspondence regarding the company’s compliance with minimum bid price requirements and confirm that the matter was resolved after the company regained compliance.
On Stock Titan, Invivyd filings are updated as they appear on EDGAR, and AI-powered tools summarize key points from each document. Users can quickly identify why a filing was made, what agreements or clinical developments it describes, and how it relates to Invivyd’s antibody pipeline, EUA-authorized PEMGARDA product, and capital-raising activities. This helps investors and researchers navigate lengthy regulatory documents and focus on the disclosures most relevant to IVVD’s business and stock.
Invivyd, Inc. provides detailed updates on its COVID-19 antibody program and unveils a new measles antibody candidate. The pivotal Phase 3 DECLARATION study of VYD2311 for pre-exposure COVID-19 prophylaxis has been upsized by about 500 participants beyond an initial 1,818, after a pre-specified, conservative, blinded sample size re-estimation showed enough events to support high-end efficacy targets. Top-line data are now expected in the third quarter of 2026, with a pediatric VYD2311 study in children 0–11 years, called DRUMMER, planned only if DECLARATION is successful. Invivyd also introduces VMS063, a highly potent, half-life-extended measles monoclonal antibody targeting the conserved Fusion protein, showing picogram- to low-nanogram-per-milliliter neutralization in vitro across key measles lineages. VMS063 has entered IND-enabling work for near-term clinical development, aimed at treatment and prophylaxis in high-risk groups amid rising U.S. measles cases and waning herd immunity.
Invivyd, Inc. is asking stockholders to vote at its virtual 2026 Annual Meeting on May 19, 2026 at 8:30 a.m. Eastern Time. Stockholders will elect six directors for one-year terms expiring at the 2027 meeting and ratify PricewaterhouseCoopers LLP as auditor for 2026.
The Board unanimously recommends voting “FOR ALL” director nominees and “FOR” auditor ratification. The meeting is fully virtual at www.virtualshareholdermeeting.com/IVVD2026, with a record date of March 20, 2026, when 282,803,863 common shares were outstanding and entitled to one vote each.
Invivyd, Inc. (IVVD) is a clinical‑stage biopharmaceutical company focused on monoclonal antibodies for serious viral infections, led by COVID‑19. Its only authorized product is PEMGARDA, an EUA‑cleared antibody for pre‑exposure COVID‑19 prophylaxis in certain moderately to severely immunocompromised patients in the U.S.
The company’s future depends heavily on PEMGARDA’s commercial uptake and continued emergency authorization, and on advancing VYD2311, a next‑generation COVID‑19 antibody now in Phase 3 prevention trials under FDA Fast Track. Invivyd is also developing VBY329 for RSV in infants and an early measles antibody program.
The filing highlights substantial doubt about the company’s ability to continue as a going concern, ongoing losses, and the need for additional funding. Invivyd relies on key partners, including WuXi Biologics for manufacturing and Adimab for antibody discovery and platform technology, and operates in a competitive landscape with vaccines, antivirals, and other antibody developers.
Invivyd, Inc. reported strong 2025 growth as net product revenue rose to $53.4M from $25.4M, driven by PEMGARDA sales, while operating expenses fell sharply. The company’s net loss narrowed to $52.5M from $169.9M, and year-end cash and equivalents increased to $226.7M, supported by over $200M raised in the second half of 2025.
PEMGARDA quarterly net product revenue reached $17.2M in Q4 2025, up 25% year over year and 31% sequentially, helping build a commercial foundation. Invivyd advanced its pipeline, fully enrolling the Phase 3 DECLARATION trial of COVID-19 antibody VYD2311, gaining Fast Track designation and targeting top-line data mid-year, while nominating RSV candidate VBY329 and planning a SPEAR Long COVID study.
Invivyd, Inc. Chief Scientific Officer Robert D. Allen III reported RSU vesting and related stock sales. He acquired 99,000 shares of common stock at $0.0000 per share through the exercise/conversion of restricted stock units and then sold 37,581 shares in open-market transactions.
The sales, at weighted average prices of $1.5396 and $1.5778 per share, were made under a non-discretionary sell-to-cover arrangement to satisfy tax withholding obligations pursuant to a Rule 10b5-1 plan. After these transactions, he directly held 114,487 shares of Invivyd common stock.
Invivyd, Inc.’s Chief Human Resources Officer Julie Green reported RSU vesting and related share sales. On February 15, she acquired 99,000 shares of common stock at $0.00 per share through the conversion of restricted stock units, increasing her direct common stock holdings.
On February 17 and 18, Green sold a total of 40,627 common shares in open-market transactions at weighted average prices of $1.5396 and $1.5778 per share. Footnotes explain these were non-discretionary “sell-to-cover” trades under a Rule 10b5-1 plan to satisfy tax withholding on the RSU vesting. After these transactions, she directly held 107,717 common shares.
Invivyd, Inc. Chief Financial Officer William E. Duke reported a mix of RSU vesting and related share sales. On February 15, 2026, he acquired 99,000 shares of common stock at no cost through the exercise of restricted stock units, leaving him with 148,344 shares.
On February 17 and 18, 2026, he sold 19,663 shares at a weighted average price of $1.5396 and 20,964 shares at a weighted average price of $1.5778 in open-market transactions. The company notes these were non-discretionary “sell-to-cover” sales to satisfy tax withholding obligations under a Rule 10b5-1 plan, and 107,717 shares of common stock remained held directly afterward.
Invivyd, Inc.’s Chief Commercial Officer Timothy Edward Lee reported a mix of stock sales and awards tied to restricted stock unit (RSU) vesting. On February 15, 2026, RSUs covering 99,000 shares were exercised at $0.00 per share and converted into common stock, with an RSU award scheduled to vest over eighteen months, one-third every six months from February 15, 2025.
On February 17 and 18, 2026, he sold a total of 40,627 common shares in open-market transactions at weighted average prices of about $1.54 and $1.58 per share. According to the disclosure, these sales were non-discretionary “sell-to-cover” transactions made solely to satisfy tax withholding obligations under a pre-established Rule 10b5-1 trading plan adopted on February 20, 2025. After these transactions, he reported owning 117,717 shares of common stock directly, including 10,000 shares acquired through the company’s Employee Stock Purchase Program, and 102,000 RSUs outstanding.
Invivyd, Inc. Chief Legal Officer and Secretary Jill Andersen reported a mix of stock activity involving restricted stock units (RSUs) and common shares. On February 15, RSUs covering 165,000 shares converted into common stock at a stated price of $0.0000 per share, reflecting an RSU vesting event. The RSU award vests over an eighteen-month period, with one-third vesting every six months following the February 15, 2025 grant date, conditioned on continued service.
To cover tax withholding from this vesting, Andersen executed non-discretionary "sell-to-cover" transactions under a Rule 10b5-1 plan adopted on February 20, 2025, selling 32,771 shares on February 17 at a weighted average price of $1.5396 and 34,939 shares on February 18 at a weighted average price of $1.5778. After these transactions, she directly held 181,736 shares of common stock, with an additional 500 shares held indirectly by her spouse.